Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Elli

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Haematologica|February 13, 2008
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatmentsValerio De Stefano, Tommaso Za, Elena Rossi, et al.
American Journal of Hematology|April 5, 2012
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPNElisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, et al.
Hematological Oncology|April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinibFrancesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Internal and Emergency Medicine|January 15, 2015
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemiaAndrea Piccin, Michael Steurer, Manfred Mitterer, et al.
Blood Cancer Journal|June 9, 2018
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B<sub>2</sub> assay as an evaluation tool of different aspirin dosing regimens in the clinical settingValerio De Stefano, Bianca Rocca, Alberto Tosetto, et al.
The New England Journal of Medicine|December 11, 2012
Cardiovascular events and intensity of treatment in polycythemia veraRoberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Blood|October 26, 2014
Recurrent ETNK1 mutations in atypical chronic myeloid leukemiaCarlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, et al.
Leukemia|January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibTiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Haematologica|February 13, 2008
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatmentsValerio De Stefano, Tommaso Za, Elena Rossi, et al.
American Journal of Hematology|April 5, 2012
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPNElisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, et al.
Hematological Oncology|April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinibFrancesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Internal and Emergency Medicine|January 15, 2015
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemiaAndrea Piccin, Michael Steurer, Manfred Mitterer, et al.
Blood Cancer Journal|June 9, 2018
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B<sub>2</sub> assay as an evaluation tool of different aspirin dosing regimens in the clinical settingValerio De Stefano, Bianca Rocca, Alberto Tosetto, et al.
The New England Journal of Medicine|December 11, 2012
Cardiovascular events and intensity of treatment in polycythemia veraRoberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Blood|October 26, 2014
Recurrent ETNK1 mutations in atypical chronic myeloid leukemiaCarlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, et al.
Leukemia|January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibTiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Pageof 2